Latest / The Well-Built Life / Revolutionizing Cartilage: New Hope for Osteoarthritis
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:06Speaker 1: you are tuning in. We are here to cut through
- 0:09Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:13Speaker 1: share simple practical habits that help you feel stronger, healthier,
- 0:17Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:21Speaker 1: and let's dive in. So, Thomas, let's dive into the
- 0:25Speaker 1: fascinating research coming out of Stanford Medicine. Essentially, They have
- 0:30Speaker 1: identified a new enzyme called 15-PGDH, which plays a critical
- 0:35Speaker 1: role in aging joint health, specifically how it hinders cartilage regeneration.
- 0:41Speaker 2: Right, and that's the crucial nuance here. We have known
- 0:44Speaker 2: for a while that cartilage is essentially a non-regenerative tissue,
- 0:48Speaker 2: but this enzyme is essentially a roadblock to the natural
- 0:52Speaker 2: regenerative processes. Can you explain how blocking this enzyme seems
- 0:57Speaker 2: to reverse cartilage loss in aging joints?
- 0:59Speaker 1: Well, in simple terms, the 15-PGDH enzyme acts as a gerozyme,
- 1:05Speaker 1: which means it accumulates with age and stops cartilage cells
- 1:08Speaker 1: from doing their usual repair work. Stanford's research showed that
- 1:13Speaker 1: when this enzyme is inhibited, the cartilage cells can actually
- 1:16Speaker 1: revert to a more youthful state, allowing for better regeneration.
- 1:20Speaker 2: That's wild when you look at the raw numbers. In
- 1:23Speaker 2: recent studies, mice treated with 15 PGDH inhibitors reversed cartilage
- 1:29Speaker 2: loss and even prevented arthritis after simulated joint injuries. So,
- 1:34Speaker 2: it's not just a temporary fix but a mechanism that
- 1:37Speaker 2: could potentially restore some youthful functionality.
- 1:40Speaker 1: Exactly. Which brings up an interesting contradiction. For years, we
- 1:44Speaker 1: have believed cartilage was a dead-end, non-regenerative tissue. This research
- 1:50Speaker 1: is really shifting that paradigm. It makes you wonder what
- 1:53Speaker 1: else might be going on in aging bodies that we
- 1:55Speaker 1: haven't discovered yet. Gotcha.
- 1:57Speaker 2: And the transition from these initial findings to human trials
- 2:01Speaker 2: is really exciting. Human cartilage samples from total knee replacements
- 2:06Speaker 2: started showing signs of regeneration within just one week of
- 2:10Speaker 2: treatment with 15 PGDH inhibitors. That's a huge leap forward
- 2:14Speaker 2: from just mice models, right?
- 2:16Speaker 1: True. The human trials are a game changer. It's not
- 2:19Speaker 1: just theoretical anymore. It's showing promise in people who are
- 2:23Speaker 1: actually suffering from the condition. It's a stark reminder of
- 2:26Speaker 1: how much more we can achieve with the right scientific breakthroughs.
- 2:30Speaker 2: And this isn't just Stanford doing the heavy lifting. The
- 2:33Speaker 2: federal government has jumped on board with the NITRO program,
- 2:37Speaker 2: investing $ 190 million. That's a big vote of confidence, isn't it?
- 2:43Speaker 2: It's taking what was a one-institution research effort and scaling
- 2:47Speaker 2: it up to a national initiative.
- 2:48Speaker 1: Absolutely. It's like going from a moonshot idea to something
- 2:52Speaker 1: tangible in just a few years. Stanford and University of
- 2:56Speaker 1: Colorado Boulder both received significant funding and both are making progress.
- 3:02Speaker 1: Regenerer Therapeutics, the company spun out of the University of
- 3:06Speaker 1: Colorado Boulder, is already moving into clinical trials, which is
- 3:10Speaker 1: incredibly promising.
- 3:12Speaker 2: Speaking of which, these therapies could change the landscape of
- 3:15Speaker 2: joint health management, but there are still a lot of questions.
- 3:19Speaker 2: How do these inhibitors work in real-world conditions, you know,
- 3:23Speaker 2: outside of the lab? And what are the long-term effects
- 3:25Speaker 2: of inhibiting this enzyme? Good point.
- 3:28Speaker 1: The efficacy in preclinical studies is impressive. But as Stephanie
- 3:32Speaker 1: Bryant from Boulder mentioned, we still need larger clinical trials
- 3:36Speaker 1: to confirm everything. Plus, the ethical considerations around using stem
- 3:41Speaker 1: cells and 3D-printed scaffolds definitely come into play. How do
- 3:45Speaker 1: we balance innovation with patient safety and long-term? term health.
- 3:50Speaker 2: Exactly ethics, efficiency, and integration with existing clinical cohorts. We
- 3:56Speaker 2: need to figure out how this all ties together without
- 3:58Speaker 2: compromising patient care. But looking at the bigger picture, these
- 4:03Speaker 2: advancements could truly redefine how we manage and treat osteoarthritis,
- 4:08Speaker 2: potentially offering a solution to millions of people.
- 4:11Speaker 1: So, Thomas, let's dive into the nitty-gritty of how 15
- 4:16Speaker 1: PGDH inhibitors work. and what's involved in this broader initiative.
- 4:21Speaker 1: How does this enzyme actually get inactivated at the cellular level?
- 4:24Speaker 2: Great question, Rachel. The key mechanism revolves around the enzyme 15-PGDH,
- 4:31Speaker 2: which is usually active in cartilage. By inhibiting this enzyme,
- 4:35Speaker 2: we allow chondrocytes, those cartilage-producing cells, to switch into a
- 4:40Speaker 2: more youthful regenerative state. Essentially, We are flipping a genetic
- 4:44Speaker 2: switch that turns off the brakes on cartilage regeneration.
- 4:48Speaker 1: Right, and that's the crucial nuance here. Can you walk
- 4:51Speaker 1: us through how this has progressed from initial lab models
- 4:55Speaker 1: to human testing?
- 4:56Speaker 2: Of course, let's break it down. Initially, Stanford Medicine did
- 5:00Speaker 2: some impressive mouse studies. When they blocked 15, PGDH, the
- 5:05Speaker 2: mice not only reversed their naturally occurring cartilage loss, but
- 5:09Speaker 2: even avoided developing arthritis after simulated injuries. Fast forward to
- 5:14Speaker 2: human testing, where samples from knee replacements started showing remarkable results.
- 5:20Speaker 2: New cartilage forming within just a week of inhibitor treatment.
- 5:24Speaker 2: That's a big deal, as it suggests the enzyme inhibition
- 5:28Speaker 2: can work in real joints when we have the right drug.
- 5:30Speaker 1: That's wild when you look at the raw numbers. But, Thomas,
- 5:35Speaker 1: in this broader federal initiative … Who are the key
- 5:38Speaker 1: players and how is the funding allocated?
- 5:41Speaker 2: ARPA-H is leading the charge with the $ 190 million NITRO program.
- 5:47Speaker 2: They are pouring resources into everything from cartilage and bone
- 5:50Speaker 2: regeneration to using innovative technologies like targeted drug delivery and
- 5:55Speaker 2: 3D printed scaffolds. The University of Colorado Boulder has been
- 5:59Speaker 2: a hotbed of development, showing successful reversal of osteoarthritis in
- 6:04Speaker 2: animal models within four to eight weeks. That's significant progress,
- 6:09Speaker 2: isn't it?
- 6:10Speaker 1: Absolutely. And Thomas, what's the current state of these clinical trials?
- 6:15Speaker 1: Are we talking about close to a marketable product? Or
- 6:18Speaker 1: are we still in the early phases?
- 6:21Speaker 2: We have got a long way to go, but we
- 6:23Speaker 2: are making good strides. The University of Colorado Boulder, led
- 6:28Speaker 2: by Stephanie Bryant, is now testing their lead candidate in
- 6:31Speaker 2: Phase II trials. It's promising. but they are still waiting
- 6:35Speaker 2: for larger, more definitive clinical trials to confirm everything. Ethical
- 6:40Speaker 2: considerations and ensuring patient safety are at the forefront.
- 6:44Speaker 1: That makes sense. So, what about the other stakeholders? Who
- 6:48Speaker 1: else is involved, and how are they contributing?
- 6:51Speaker 2: Regenerare Therapeutics, the company set up by the University of
- 6:55Speaker 2: Colorado Boulder, is taking the lead on commercializing these therapies,
- 7:00Speaker 2: then to raise the broader scientific community. like Columbia University,
- 7:05Speaker 2: which is exploring 3D-printed scaffolds with stem cells. This multidisciplinary
- 7:10Speaker 2: approach ensures that all angles are covered from the basic
- 7:13Speaker 2: science to translational research.
- 7:16Speaker 1: And on that note, how do you see the future
- 7:18Speaker 1: of this treatment looking? Are there any specific data points
- 7:22Speaker 1: or outcomes we should be paying attention to?
- 7:25Speaker 2: Well, we have some compelling data. For instance, semaglutide, a
- 7:30Speaker 2: drug primarily used for weight management. also seems effective in
- 7:34Speaker 2: reducing joint pain and cartilage degeneration in obese individuals. This
- 7:39Speaker 2: opens up a whole new pathway for managing joint health,
- 7:43Speaker 2: leveraging existing clinical cohorts. The future looks exciting, but we
- 7:48Speaker 2: need to ensure it's both effective and safe for the
- 7:50Speaker 2: millions of people affected by osteoarthritis.
- 7:53Speaker 1: So, Thomas, let's dive into the nitty-gritty of the latent
- 7:56Speaker 1: contradictions and critical debates surrounding these new treatments. We know
- 8:02Speaker 1: that the traditional view of cartilage as non-regenerative is being
- 8:06Speaker 1: upended by the discovery of 15-PGDH. But what are the
- 8:11Speaker 1: actual contradictions we should be looking at?
- 8:14Speaker 2: Right, and that's the crucial nuance here, Rachel. In the past,
- 8:17Speaker 2: the scientific community generally accepted that cartilage was essentially a
- 8:21Speaker 2: non-regenerative tissue. However, the data emerging from the 15-PGDH research
- 8:27Speaker 2: is fundamentally challenging that belief. This new view could alter
- 8:31Speaker 2: our understanding of joint health and regeneration, opening up entirely
- 8:36Speaker 2: new treatment pathways.
- 8:37Speaker 1: Exactly. Let's dissect this. For instance, the fact that semaglutide,
- 8:42Speaker 1: a drug typically used to manage weight, shows promise in
- 8:45Speaker 1: reducing joint pain and cartilage degeneration in obese individuals suggests
- 8:50Speaker 1: that the underlying mechanisms might be more intertwined than previously thought.
- 8:55Speaker 1: But how do we reconcile this? with the basic biology
- 8:58Speaker 1: of cartilage.
- 8:59Speaker 2: This is where the contradiction comes in. If semaglutide can
- 9:03Speaker 2: have direct effects on joint health, it means we might
- 9:06Speaker 2: be missing something fundamental in our current understanding of how
- 9:10Speaker 2: these regulatory pathways operate. It's a reminder that even in
- 9:14Speaker 2: seemingly unrelated conditions, there are commonalities that we might be
- 9:18Speaker 2: able to exploit. Right.
- 9:20Speaker 1: And this complexity brings up an ethical debate too. The
- 9:24Speaker 1: use of stem cells and 3D. printed scaffolds in joint regeneration,
- 9:29Speaker 1: is both a huge leap forward and a potential long-term
- 9:33Speaker 1: commitment for patients. How can we ensure that these interventions
- 9:38Speaker 1: are not only effective in the short term, but sustainable
- 9:41Speaker 1: and accessible in the long run?
- 9:43Speaker 2: That's a great point, Rachel. The ethical considerations are vast.
- 9:48Speaker 2: On one hand, these technologies could provide transformative treatment options
- 9:52Speaker 2: for millions currently suffering from osteoarthritis. On the other, The
- 9:57Speaker 2: reliance on external treatments can create significant dependencies that might
- 10:01Speaker 2: lead to long-term financial and health burdens for patients. We
- 10:06Speaker 2: need to consider not only the immediate benefits, but also
- 10:09Speaker 2: the broader social impacts.
- 10:11Speaker 1: Exactly. Which brings up an interesting contradiction. The efficiency of
- 10:16Speaker 1: 15 PGDH inhibitors and the integration of existing clinical data
- 10:21Speaker 1: from weight management drugs, like semaglutide, seem promising. But how
- 10:26Speaker 1: do we navigate the complex regulatory landscape without compromising patient
- 10:31Speaker 1: safety and privacy?
- 10:33Speaker 2: True. The integration of these new treatments into existing clinical
- 10:37Speaker 2: frameworks is fraught with challenges. We need to balance the
- 10:41Speaker 2: speed of research and development with rigorous testing and validation.
- 10:45Speaker 2: The traditional model for clinical trials might not be sufficient
- 10:49Speaker 2: given the potential for rapid innovation in this field.
- 10:52Speaker 1: Precisely. The key is adapting the existing infrastructure to accommodate
- 10:56Speaker 1: these new approaches. We need to ensure that the data
- 10:59Speaker 1: from weight management drugs can be effectively leveraged while maintaining
- 11:03Speaker 1: high standards of rigor and privacy.
- 11:06Speaker 2: Absolutely. It's all about finding that balance. The future of
- 11:10Speaker 2: osteoarthritis treatment is looking exciting. But it's also fraught with
- 11:14Speaker 2: complexities that need to be carefully managed to ensure we
- 11:18Speaker 2: are developing treatments that are truly effective and safe.
- 11:21Speaker 1: So Thomas, let's delve into the key questions we have
- 11:24Speaker 1: yet to fully answer. How do we bridge the gap
- 11:27Speaker 1: between successful animal models and human subjects in the context
- 11:30Speaker 1: of 15 PGDH inhibitors?
- 11:33Speaker 2: Great question, Rachel. The main challenge is ensuring that what
- 11:37Speaker 2: works in mice and other animal models translates to humans.
- 11:41Speaker 2: We know that sometimes what seems promising in preclinical studies
- 11:44Speaker 2: doesn't pan out in clinical trials. What specific ethical concerns
- 11:49Speaker 2: arise here?
- 11:50Speaker 1: Exactly. Those are the big questions, and it's not just
- 11:53Speaker 1: about safety. It's also about the long-term effects on human health.
- 11:58Speaker 1: For instance, what are the potential side effects of long-term
- 12:02Speaker 1: use of 15 PGDH inhibitors?
- 12:05Speaker 2: That's a critical point. There could be unforeseen impacts on
- 12:09Speaker 2: overall health. The immune system might be compromised, for example.
- 12:14Speaker 2: On the other hand, to raise also the issue of
- 12:17Speaker 2: patient compliance, how do we ensure patients adhere to treatment
- 12:20Speaker 2: protocols without causing undue distress? Right.
- 12:24Speaker 1: It's about finding that balance. Another key aspect is adapting
- 12:28Speaker 1: the current clinical infrastructure. How do we integrate these new
- 12:32Speaker 1: treatments into existing protocols without compromising the high standards of care?
- 12:37Speaker 2: You hit the nail on the head. We need flexible,
- 12:40Speaker 2: adaptable systems. For example, how do we ensure that data
- 12:44Speaker 2: collected from semaglutide treatment on weight management can be usefully
- 12:49Speaker 2: integrated into our clinical models for osteoarthritis? It's about leveraging
- 12:53Speaker 2: existing cohorts to accelerate progress.
- 12:56Speaker 1: Exactly. That's the crux of it. We need to think
- 13:00Speaker 1: creatively about how to use these existing data sets. It's
- 13:03Speaker 1: not just about applying what works. It's about refining the
- 13:06Speaker 1: approach based on what's already out there. What would be
- 13:09Speaker 1: the most effective way to do that?
- 13:11Speaker 2: It's about smart collaboration. We need clinicians, researchers, and patients
- 13:15Speaker 2: to work closely together. Patient privacy is paramount, but we
- 13:20Speaker 2: also need open data sharing for faster breakthroughs. There might
- 13:23Speaker 2: be technological hurdles to overcome, like ensuring data interoperability across
- 13:28Speaker 2: different systems. True.
- 13:30Speaker 1: There is a lot of ground to cover. The future
- 13:33Speaker 1: outlook is promising, but we need to be mindful of
- 13:36Speaker 1: these challenges. How do you see the landscape evolving over
- 13:40Speaker 1: the next few years?
- 13:41Speaker 2: I think we will see more interdisciplinary approaches. The combination
- 13:45Speaker 2: of engineering, biology, and clinical data is key. Tools like
- 13:50Speaker 2: 3D printing and advanced drug delivery systems will likely play
- 13:54Speaker 2: a bigger role. We might also see a surge in
- 13:58Speaker 2: personalized medicine. Tailoring treatments to individual patients needs more precisely.
- 14:03Speaker 1: That sounds thrilling. It's a complex field, but the potential
- 14:07Speaker 1: to change millions of lives is incredible. Thank you, Thomas,
- 14:11Speaker 1: for those insights. It's clear that Turi's a lot of
- 14:15Speaker 1: work to do, but we are well on our way.
- 14:17Speaker 2: As we look toward the future, it's fascinating to see
- 14:20Speaker 2: how multidisciplinary approaches are not just being considered, they are
- 14:24Speaker 2: being implemented on a grand scale. Take the ARPA-H and
- 14:28Speaker 2: its NITRO program, for instance. It's truly transformative to see
- 14:32Speaker 2: such a huge initiative dedicated to tackling osteoarthritis at its roots.
- 14:37Speaker 1: Absolutely, Thomas. The NITRO program is just one example of
- 14:41Speaker 1: how researchers are stepping out of their comfort zones and
- 14:44Speaker 1: pushing the boundaries. The $ 190 million investment isn't just about money.
- 14:50Speaker 1: It's about recognizing the potential for game, changing therapies. But
- 14:55Speaker 1: what exactly does this mean for the patients?
- 14:57Speaker 2: Well, first of all, It means the possibility of targeted
- 15:01Speaker 2: drug delivery and 3D-printed scaffolds that are more precise and effective.
- 15:06Speaker 2: For instance, the University of Colorado Boulder's lead drug candidate
- 15:11Speaker 2: has shown promise in reversing osteoarthritis within four to eight weeks.
- 15:15Speaker 2: That's life, changing for someone dealing with chronic pain.
- 15:19Speaker 1: That's incredibly exciting, but let's talk about the challenges. How
- 15:23Speaker 1: do these therapies translate from preclinical success to clinical settings?
- 15:28Speaker 1: It's a huge leap, especially with such a complex condition
- 15:32Speaker 1: like osteoarthritis.
- 15:33Speaker 2: Exactly. The translation phase is critical. We need more data
- 15:38Speaker 2: to ensure these therapies are not only effective but safe.
- 15:42Speaker 2: There are also the ethical considerations to address, particularly with
- 15:46Speaker 2: the use of stem cells and biomaterials. How do we
- 15:50Speaker 2: balance innovation with the patient's well-being? True.
- 15:53Speaker 1: And the integration of semaglutide data is something to watch.
- 15:57Speaker 1: This drug, used for weight management, has shown promise in
- 16:00Speaker 1: alleviating joint issues. It's a reminder that sometimes the answers
- 16:05Speaker 1: to our problems are hiding in plain sight, just waiting
- 16:08Speaker 1: to be repurposed.
- 16:09Speaker 2: Definitely. It's a pragmatic approach that leverages existing clinical data.
- 16:15Speaker 2: But how do we handle the privacy concerns and regulatory hurdles?
- 16:19Speaker 2: Ensuring that these therapies are approved and widely accessible is
- 16:23Speaker 2: going to be a significant hurdle. Agreed.
- 16:26Speaker 1: And we can't forget the efficiency of these therapies. Can
- 16:30Speaker 1: they work in the real world as they do in
- 16:32Speaker 1: controlled studies? I think the upcoming clinical trials will give
- 16:36Speaker 1: us some solid answers. Right.
- 16:39Speaker 2: And these trials will be crucial. They will not only
- 16:42Speaker 2: validate the efficacy, but also give us insight into the
- 16:45Speaker 2: long-term effects of 15 PGDH inhibition therapies. It's a complex process,
- 16:51Speaker 2: but one that could lead to revolutionary changes in how
- 16:54Speaker 2: we approach osteoarthritis.
- 16:56Speaker 1: Absolutely. And with these advancements, the potential for improving the
- 17:01Speaker 1: quality of life for millions of people is immense. It's
- 17:05Speaker 1: an exciting time for both researchers and patients alike. That
- 17:09Speaker 1: brings us to the end of today's episode. Thank you
- 17:11Speaker 1: so much for spending part of your day with me.
- 17:14Speaker 1: If you found this episode's tips helpful and want to
- 17:16Speaker 1: make sure you don't miss the next conversation, Please take
- 17:20Speaker 1: a quick second to hit that subscribe or follow button
- 17:22Speaker 1: on whatever platform you are listening on. It's a completely
- 17:26Speaker 1: free way to support the show and helps more people
- 17:28Speaker 1: find us. This podcast is independently produced, so if you
- 17:32Speaker 1: are ever in a position where you would like to
- 17:34Speaker 1: help keep it running, we do accept small donations. You
- 17:38Speaker 1: can find a link right in the episode description below
- 17:40Speaker 1: to buy us a coffee or contribute what you can.
- 17:43Speaker 1: Every bit genuinely helps. Take care of yourself. Stay balanced.
- 17:48Speaker 1: And we will talk again soon.